Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
Alimentary Pharmacology & Therapeutics2022Vol. 57(1), pp. 72–80
Citations Over TimeTop 10% of 2022 papers
Yu Kyung Cho, Jae Hak Kim, Hyun‐Soo Kim, Tae Oh Kim, Jung Hwan Oh, Suck Chei Choi, Jeong Seop Moon, Sang Kil Lee, Sung Woo Jung, Sung Soo Kim, Hye‐Kyung Jung, Sang Pyo Lee, Gab‐Jin Cheon, Moo In Park, Hwoon‐Yong Jung, Kwang Hyun Ko, In‐Kyung Sung, Si Hyung Lee, Ju Yup Lee, Soo Teik Lee, Poong‐Lyul Rhee, Nayoung Kim, Su Jin Hong, Hyun Jin Kim, Gwang Ha Kim, Kwang Jae Lee, Sung Kook Kim, Woon Geon Shin, Oh Young Lee
Abstract
Tegoprazan 25 mg was non-inferior to lansoprazole 15 mg in maintenance of healing of mild EE. In this study, tegoprazan had a similar safety profile to lansoprazole.
Related Papers
- → Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long‐term comparative study(1998)35 cited
- → Lansoprazole vs. omeprazole for gastro‐oesophageal reflux disease: a pH‐metric comparison(2002)23 cited
- [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].(1993)
- → Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat(1995)7 cited
- Comparison Observation of Lansoprazole and Omeprazole Treatment of Gerd(2012)